Cumberland Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $9,085 | $9,848 | $8,497 | $9,353 |
Gross Profit | 7,762 | 6,998 | 5,771 | 6,627 |
EBITDA | 13 | 459 | -336 | -4,030 |
EBIT | -1,388 | -964 | -1,772 | -6,098 |
Net Income | -1,544 | -1,085 | -1,946 | -6,291 |
Net Change In Cash | 9,085 | 9,848 | 8,497 | 9,353 |
Free Cash Flow | 516 | -902 | -2,194 | 953 |
Cash | 17,464 | 17,336 | 18,548 | 18,321 |
Basic Shares | 14,052 | 14,118 | 14,098 | 14,164 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $39,552 | $42,010 | $35,985 | $37,441 |
Gross Profit | 33,485 | 32,892 | 27,173 | 28,788 |
EBITDA | 153 | 332 | -857 | -1,557 |
EBIT | -5,617 | -4,995 | -5,464 | -6,306 |
Net Income | -6,279 | -5,650 | -5,597 | -6,625 |
Net Change In Cash | 39,552 | 42,010 | 35,985 | 37,441 |
Cost of Revenue | -3,458 | |||
Free Cash Flow | 5,640 | 6,379 | 5,987 | 3,301 |
Cash | 18,321 | 19,757 | 27,040 | 24,753 |
Basic Shares | 14,298 | 14,563 | 14,904 | 15,162 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.10 |
2024-06-30 | -$0.07 |
2024-03-31 | -$0.13 |
2023-12-31 | -$0.44 |
